Faculty

Jae Hyun Kim

Experience sharing: Optimizing CPP patient care with long-acting GnRHa

For the treatment of central precocious puberty (CPP), depot formulation of GnRH agonist (GnRHa) has been widely used as a standard treatment. In Korea, mainstay of GnRHa treatment for CPP has been monthly depot formulation. However, recent approval of 3-month and 6-month depot formulation of GnRHa in Korea showed a gradual increase in use of these agents for patient with CPP. Many clinical research showed that longer-acting GnRHa could effectively suppress the hypothalamic-pituitarygonadal axis and gonadotropin secretion in children with CPP. The clinical benefits also have been reported such as regression of pubertal progression, delayed maturation of bone age and increased adult height. Moreover, recent Korean studies showed that clinical efficacy of 3-month depot formulation of GnRHa for CPP. There was no difference between 1- and 3- month depot formulation in terms of switching during treatment. One-year efficacy of 1- and 3-month formulation showed comparable results. Because longer-acting GnRHa offers improved convenience and compliance, especially in a pandemic period, these could be an alternative and viable strategy for treatment of CPP.

Return to Faculty List